Autolus Therapeutics plc (AUTL) Income Statement
AUTL 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsAUTL revenue and net income
Where AUTL's revenue goes
2025Each bar shows an amount and its share of revenue. AUTL kept −381.4% of revenue as net income.
AUTL profit margins
AUTL growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +646.7% | +130.2% | +113.2% | +51.2% |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
AUTL quarterly EPS vs estimates
Autolus Therapeutics beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 11, 2026 (estimate $-0.21).
AUTL income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $75.6M | $10.1M | $1.7M | $6.2M | $1.5M | $1.7M | $2.9M | $1.0M | $1.0M | $1.7M |
| Cost of revenue | $96.6M | $141.0M | $6.6M | $137.2M | $128.7M | $134.9M | $105.4M | $48.3M | $48.3M | $1.0M |
| Gross profit | −$21.0M | −$130.9M | $1.7M | $6.2M | $1.5M | −$133.2M | −$102.5M | −$47.3M | −$47.3M | $684,000 |
| Research & development | $128.6M | $158.1M | $130.5M | $117.4M | $110.8M | $135.0M | $105.6M | $24.6M | $24.6M | $16.0M |
| Sales, general & admin | $131.9M | $101.1M | $47.8M | $31.9M | $31.9M | $35.0M | $39.5M | $16.8M | $16.8M | $9.1M |
| Total operating expenses | $260.4M | $110.5M | $181.4M | $149.1M | $141.9M | $170.0M | $145.1M | $41.5M | $41.5M | $25.1M |
| Operating income | −$281.4M | −$241.4M | −$179.7M | −$142.9M | −$140.4M | −$303.1M | −$247.6M | −$57.5M | −$57.5M | −$23.4M |
| Interest income | $19.0M | $32.4M | $11.9M | $1.7M | $262,000 | $536,000 | $2.5M | $660,000 | $1.5M | $84,000 |
| Interest expense | $36.8M | $9.3M | $45.1M | $8.9M | $1.1M | $1.9M | $1.1M | $12,667 | $12,667 | $38,000 |
| Income before taxes | −$296.8M | −$219.1M | −$208.4M | −$148.6M | −$142.0M | −$166.3M | −$108.7M | −$36.3M | −$36.3M | −$23.4M |
| Income taxes | −$8.6M | $1.5M | −$19,000 | $272,000 | $58,000 | −$24.2M | $15.2M | −$5.2M | −$5.2M | −$3.7M |
| Net income | −$288.2M | −$220.7M | −$208.4M | −$148.8M | −$142.1M | −$142.1M | −$123.8M | −$31.1M | −$31.1M | −$19.7M |
| EBITDA | −$250.3M | −$233.1M | −$156.8M | −$132.2M | −$132.5M | −$162.5M | −$137.4M | −$50.3M | −$35.2M | −$22.4M |
| EPS (diluted) | −$1.08 | −$0.86 | −$1.20 | −$1.57 | −$1.98 | −$2.77 | −$2.79 | −$1.93 | −$0.79 | −$1.25 |
| Gross margin | −27.8% | −1,293.5% | 100.0% | 100.0% | 100.0% | −7,765.2% | −3,525.1% | −4,520.4% | −4,520.4% | 40.4% |
| Operating margin | −372.4% | −2,385.6% | −10,583.1% | −2,307.0% | −9,314.8% | −17,675.4% | −8,513.8% | −5,503.7% | −5,503.7% | −1,383.2% |
| Net margin | −381.4% | −2,180.5% | −12,272.3% | −2,403.0% | −9,429.1% | −8,285.4% | −4,258.9% | −2,976.5% | −2,976.5% | −1,165.2% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $45.7M | $26.2M | $24.3M | $21.2M | $20.9M | $9.0M | $29,000 | $0 | $0 | $10.1M | $1.8M | $406,000 |
| Cost of revenue | $20.5M | $24.6M | $25.3M | $28.6M | $24.4M | $18.0M | $138.3M | $1.2M | $1.9M | $1.8M | $1.8M | $1.5M |
| Gross profit | $25.2M | $1.6M | −$1.0M | −$7.4M | −$3.5M | −$9.0M | −$138.3M | −$1.2M | −$1.9M | $8.3M | −$1.8M | −$1.1M |
| Research & development | $27.9M | $21.2M | $35.6M | $27.9M | $27.4M | $26.7M | $50.5M | $40.3M | $36.6M | $30.7M | $25.2M | $32.3M |
| Sales, general & admin | $41.2M | $40.0M | $35.8M | $36.3M | $30.3M | $29.5M | $67.4M | $27.3M | $21.9M | $18.2M | $15.7M | $10.6M |
| Total operating expenses | $69.1M | $61.2M | $71.3M | $64.2M | $57.7M | $56.3M | $103.2M | $67.7M | $58.9M | $47.0M | $39.1M | $42.9M |
| Operating income | −$43.8M | −$59.5M | −$72.4M | −$71.6M | −$61.2M | −$65.2M | −$241.4M | −$68.9M | −$58.9M | −$38.8M | −$40.9M | −$44.0M |
| Interest income | $1.9M | $2.5M | $3.2M | $4.4M | $12.1M | $6.1M | $7.4M | $8.3M | $9.7M | $6.9M | $3.0M | $3.6M |
| Interest expense | $2.7M | $11.1M | $22.8M | $10.5M | $6.8M | $10.1M | $30.8M | $10.7M | $10.2M | $19.3M | $30.1M | $5.0M |
| Income before taxes | −$38.6M | −$70.7M | −$91.4M | −$78.6M | −$47.5M | −$67.9M | −$26.1M | −$82.1M | −$58.2M | −$52.7M | −$64.8M | −$45.9M |
| Income taxes | $465,000 | $861,553 | −$1.2M | $532,000 | $397,000 | $2.2M | $1.5M | $22,000 | $51,000 | −$8,000 | $12.4M | −$21,000 |
| Net income | −$39.1M | −$71.6M | −$90.2M | −$79.1M | −$47.9M | −$70.2M | −$27.6M | −$82.1M | −$58.3M | −$52.7M | −$77.2M | −$45.8M |
| EBITDA | −$33.3M | −$56.9M | −$66.0M | −$64.7M | −$43.2M | −$55.5M | −$73.8M | −$65.7M | −$43.9M | −$31.6M | −$32.9M | −$41.1M |
| EPS (diluted) | −$0.15 | −$0.27 | −$0.34 | −$0.30 | −$0.18 | −$0.26 | −$0.09 | −$0.31 | −$0.22 | −$0.24 | −$0.45 | −$0.26 |
| Gross margin | 55.2% | 6.3% | −4.3% | −35.1% | −16.8% | −99.9% | −476,810.3% | — | — | 82.1% | −100.0% | −275.6% |
| Operating margin | −95.9% | −227.0% | −298.3% | −337.9% | −292.6% | −726.3% | −832,503.4% | — | — | −384.1% | −2,303.4% | −10,849.3% |
| Net margin | −85.6% | −273.1% | −371.9% | −373.3% | −229.0% | −781.1% | −95,193.1% | — | — | −522.1% | −4,347.7% | −11,292.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in AUTL's financial statements (latest annual report filed March 27, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
AUTL financial results
In fiscal year 2025 (ended December 31, 2025), Autolus Therapeutics reported revenue of $75.6 million, up 646.7% from the year before. It had a net loss of $288.2 million, a net profit margin of −381.4%. Diluted earnings per share came to −$1.08. Over five years revenue grew at an average rate of 113.2% a year.
See the AUTL stock overview for the latest quote and news, or the AUTL chart for price history and technical indicators.
AUTL income statement FAQ
What is Autolus Therapeutics's annual revenue?
Autolus Therapeutics reported total revenue of $75.6 million for fiscal year 2025, which ended on December 31, 2025. That was up 646.7% from $10.1 million the previous year.
Is Autolus Therapeutics profitable?
No. Autolus Therapeutics reported a net loss of $288.2 million in fiscal 2025, a net profit margin of −381.4%; its operating margin was −372.4%.
What is Autolus Therapeutics's gross margin?
Autolus Therapeutics's gross margin was −27.8% in fiscal 2025: for every $100 of revenue, Autolus Therapeutics kept $-28 after the direct cost of its products and services.
How much does Autolus Therapeutics spend on research and development?
Autolus Therapeutics spent $128.6 million on research and development in fiscal 2025, 170.2% of revenue.
How fast is Autolus Therapeutics growing?
Revenue grew 113.2% a year on average over the last five fiscal years, from $1.7 million to $75.6 million.
What are Autolus Therapeutics's earnings per share?
Autolus Therapeutics earned $-1.08 per diluted share in fiscal 2025, compared with $-0.86 a year earlier.
When will Autolus Therapeutics report its next earnings?
Autolus Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does Autolus Therapeutics's fiscal year end?
Autolus Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 27, 2026.